"rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies

PLoS Pathogens

Volumn 7, Issue 6, 2011, Pages

  Dimitrov, Jordan D ^a,b   Kazatchkine, Michel D ^c   Kaveri, Srinivas V ^a,b   Lacroix Desmazes, Sebastien ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c TUBERCULOSIS AND MALARIA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; ENTROPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOLECULAR DYNAMICS; VACCINE PRODUCTION; VIRUS ATTACHMENT; VIRUS MUTATION; VIRUS PATHOGENESIS; ADAPTATION; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CROSS REACTION; DEFENSE MECHANISM; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW;

ADAPTATION, PHYSIOLOGICAL; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CROSS REACTIONS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; RATIONALIZATION;

EID: 79959840591     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002095     Document Type: Article

References (44)

1. Mascola JR, Montefiori DC, (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444.
2. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
3. Pantophlet R, Burton DR, (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
4. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
5. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
6. Stamatatos L, Morris L, Burton DR, Mascola JR, (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870.
7. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
8. Kwong PD, Wilson IA, (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-578.
9. Joyce JG, ter Meulen J, (2010) Pushing the envelope on HIV-1 neutralization. Nat Biotechnol 28: 929-931.
10. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
11. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
12. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.
13. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159.
14. Choe H, Li W, Wright PL, Vasilieva N, Venturi M, et al. (2003) Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114: 161-170.
15. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107: 11483-11488.
16. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467: 591-595.
17. Notkins AL, (2004) Polyreactivity of antibody molecules. Trends Immunol 25: 174-179.
18. Eisen HN, Chakraborty AK, (2010) Evolving concepts of specificity in immune reactions. Proc Natl Acad Sci U S A 107: 22373-22380.
19. Ehrenstein MR, Notley CA, (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10: 778-786.
20. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, et al. (1999) Control of early viral and bacterial distribution and disease by natural antibodies. Science 286: 2156-2159.
21. Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, et al. (2007) The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 1: 51-61.
22. Klein JS, Bjorkman PJ, (2010) Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6: e1000908 doi:10.1371/journal.ppat.1000908.
23. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178: 4424-4435.
24. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR, (2010) Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 107: 1529-1534.
25. Diskin R, Marcovecchio PM, Bjorkman PJ, (2010) Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol 17: 608-613.
26. Manivel V, Sahoo NC, Salunke DM, Rao KV, (2000) Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 13: 611-620.
27. Manivel V, Bayiroglu F, Siddiqui Z, Salunke DM, Rao KV, (2002) The primary antibody repertoire represents a linked network of degenerate antigen specificities. J Immunol 169: 888-897.
28. Leder L, Berger C, Bornhauser S, Wendt H, Ackermann F, et al. (1995) Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide-antibody recognition. Biochemistry 34: 16509-16518.
29. Cooper A, (1999) Thermodynamic analysis of biomolecular interactions. Curr Opin Chem Biol 3: 557-563.
30. Komissarov AA, Deutscher SL, (1999) Thermodynamics of Fab-ssDNA interactions: contribution of heavy chain complementarity determining region 3. Biochemistry 38: 14631-14637.
31. Swaminathan CP, Nandi A, Visweswariah SS, Surolia A, (1999) Thermodynamic analyses reveal role of water release in epitope recognition by a monoclonal antibody against the human guanylyl cyclase C receptor. J Biol Chem 274: 31272-31278.
32. Kang J, Warren AS, (2007) Enthalpy-entropy compensation in the transition of a monospecific antibody towards antigen-binding promiscuity. Mol Immunol 44: 3623-3624.
33. Schreiber G, Keating AE, (2011) Protein binding specificity versus promiscuity. Curr Opin Struct Biol 21: 50-61.
34. Jimenez R, Salazar G, Yin J, Joo T, Romesberg FE, (2004) Protein dynamics and the immunological evolution of molecular recognition. Proc Natl Acad Sci U S A 101: 3803-3808.
35. James LC, Roversi P, Tawfik DS, (2003) Antibody multispecificity mediated by conformational diversity. Science 299: 1362-1367.
36. James LC, Tawfik DS, (2003) Conformational diversity and protein evolution--a 60-year-old hypothesis revisited. Trends Biochem Sci 28: 361-368.
37. Zimmermann J, Romesberg FE, Brooks CL, 3rd, Thorpe IF, (2010) Molecular description of flexibility in an antibody combining site. J Phys Chem B 114: 7359-7370.
38. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC, (1997) Structural insights into the evolution of an antibody combining site. Science 276: 1665-1669.
39. Li Y, Lipschultz CA, Mohan S, Smith-Gill SJ, (2001) Mutations of an epitope hot-spot residue alter rate limiting steps of antigen-antibody protein-protein associations. Biochemistry 40: 2011-2022.
40. Sinha N, Mohan S, Lipschultz CA, Smith-Gill SJ, (2002) Differences in electrostatic properties at antibody-antigen binding sites: implications for specificity and cross-reactivity. Biophys J 83: 2946-2968.
41. Kourentzi K, Srinivasan M, Smith-Gill SJ, Willson RC, (2008) Conformational flexibility and kinetic complexity in antibody-antigen interactions. J Mol Recognit 21: 114-121.
42. Pashov A, MacLeod S, Saha R, Perry M, VanCott TC, et al. (2005) Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology 15: 994-1001.
43. Pashov A, Garimalla S, Monzavi-Karbassi B, Kieber-Emmons T, (2009) Carbohydrate targets in HIV vaccine research: lessons from failures. Immunotherapy 1: 777-794.
44. Pope M, Gezelter S, Gallo N, Hoffman L, Steinman RM, (1995) Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med 182: 2045-2056.